HCAT Stock Recent News

The average of price targets set by Wall Street analysts indicates a potential upside of 75.2% in Health Catalyst (HCAT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

SALT LAKE CITY , May 21, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced the launch of Health Catalyst Ignite® , a next-generation healthcare data and analytics ecosystem that combines best-in-class technologies, healthcare-specific data models, self-service tools, and industry expertise in one modern environment. Today's health systems face significant challenges in navigating a path to clinical, operational, and financial success.

Health Catalyst, Inc. (NASDAQ:HCAT ) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Jack Knight - VP, Investor Relations Daniel Burton - CEO & Director Jason Alger - CFO Conference Call Participants Jared Haase - William Blair & Co. Elizabeth Anderson - Evercore ISI Anna Kruszenski - Barclays Capital John Ransom - Raymond James Daniel Grosslight - Citigroup Jenny Shen - BTIG Mitchell Ostrovsky - Guggenheim Securities Stan Berenshteyn - Wells Fargo & Co. Operator Good afternoon, everyone, and welcome to the Health Catalyst First Quarter 2024 Earnings Conference Call. [Operator Instructions].

The headline numbers for Health Catalyst (HCAT) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Health Catalyst (HCAT) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.05 per share a year ago.

Get a deeper insight into the potential performance of Health Catalyst (HCAT) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Health Catalyst (HCAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

The mean of analysts' price targets for Health Catalyst (HCAT) points to a 53.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

A few Zacks Medical Info Systems industry stocks like Inspire Medical Systems (INSP), Talkspace (TALK) and Health Catalyst (HCAT) are expected to gain from the new normal trends.

Health Catalyst reported strong Q4 results, meeting guidance and showing growth in technology and professional services revenue. The drop in HCAT's share price presents a buying opportunity, as the company's growth initiatives, such as its TEMS offering and next-gen data platform, are expected to drive growth and margin expansion. HCAT's long-term guidance of exceeding $100 million in EBITDA by FY28 is achievable, and its valuation should improve as it demonstrates execution and margin expansion.